UNSPSC 51271922: Procaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C13H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95URV01IDQ, chemically known as procaine, base but more generally known as procaine hydrochloride, which bears US NIH Compound Identifier 4914. European Medicines Agency schedules Procaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04046MIG.

Most nations, for tariff and trade purposes, schedule procaine hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, PROCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Procaine hydrochloride bears US NLM identifiers UMLS ID C0358490 and NCI Concept Code C47688. SMILES: CCN(CC)CCOC(=O)C1CCC(CC1)N.CL.

UNSPSC 51271922 Procaine hydrochloride is a Commodity code encompassing pharmaceutical raw materials and finished-dose products supplied through state and local cooperative purchasing agreements. State and local governments procure procaine hydrochloride and related generic multi-source pharmaceuticals primarily through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions, schools, hospitals, and other facilities. The work involves manufacturers and wholesalers supplying pharmaceuticals with verified National Drug Codes, current Good Manufacturing Practices certification, and Drug Supply Chain Security Act compliance to authorized distribution partners. Procurement bodies include state departments of administration, cooperative alliances spanning multiple states, and the health and human services systems they serve. Vendors must maintain relationships with established pharmaceutical wholesalers, provide detailed product specifications and pricing in multiple formats, carry comprehensive liability and network security insurance, and accept performance metrics tied to reporting timelines and supply chain compliance.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (solicitation S1070000015802) for generic multi-source pharmaceuticals and over-the-counter products with a March 26, 2026 response deadline, targeting award in mid-2026 for July 1, 2026 contract effectiveness. The opportunity spans Minnesota and Oregon with pricing weighted heavily on competitiveness (75 percent), administrative compliance (5 percent), EDI capability (5 percent), and fixed pricing for the contract term (10 percent). Awarded vendors supply through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with a two-year initial contract term and optional extensions. The RFP imposed a 3 percent administrative fee on all purchases and performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific dollar value or set-aside restrictions appear in the published documentation.